Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes

Reps are promoting Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes.

Tradjenta (linagliptin) is a "me too"...similar to Onglyza (saxagliptin) and Januvia (sitagliptin). These prolong incretin activity to stimulate insulin and reduce glucagon release.

Tradjenta's only real claim to fame is that it doesn't require a lower dose for patients with impaired renal function.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote